New Phase II data show vast majority of patients experiencing no relapses or disability progression
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 50 mg of Astellas Pharma Global Development
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
Phase 3 study results will form the basis for future discussions with global regulatory authorities
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
Subscribe To Our Newsletter & Stay Updated
